Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05084963 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Efficacy, Safety and Tolerability of IRL201104 in Adults With Active Eosinophilic Esophagitis
A Phase 2 study, sponsored by Revolo Biotherapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT05084963: Completed Phase 2 study, sponsored by Revolo Biotherapeutics.
NCT05084963 is a Phase 2 study that has completed, run by Revolo Biotherapeutics. The registered enrollment target is 36 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05084963, a Phase 2 study, has completed, sponsored by Revolo Biotherapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
The purpose of this study is to asses the efficacy, safety and tolerability of repeat doses of IRL201104 in Adult Participants with Active Eosinophilic Esophagitis (EoE)
Primary Outcome
The change from baseline in histologic eosinophil count in each treatment group will be summarized as the mean and Standard Deviation (SD)
Interventions
- DRUG Placebo
- DRUG IRL201104
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2021-10-29 |
| Est. Completion | 2022-10-24 |
| Phase | Phase 2 |
What the finished NCT05084963 record still lists
NCT05084963 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (73% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05084963 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05084963 about?
NCT05084963 is a clinical study titled "A Study to Assess the Efficacy, Safety and Tolerability of IRL201104 in Adults With Active Eosinophilic Esophagitis". The purpose of this study is to asses the efficacy, safety and tolerability of repeat doses of IRL201104 in Adult Participants with Active Eosinophilic Esophagitis (EoE)
What is the current status of trial NCT05084963?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2021-10-29. Estimated completion is 2022-10-24.
What interventions are being tested in trial NCT05084963?
The interventions under investigation include: Placebo (DRUG), IRL201104 (DRUG).
Who is sponsoring clinical trial NCT05084963?
This trial is sponsored by Revolo Biotherapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05084963's enrollment target sits among peer trials
36 1496th of 2000 higher than 477 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI